| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2013058691 |
| Title |
Method for Inhibition of Deubiquitinating Activity. |
| Abstract |
A compound of the general structure (I) is capable of abrogating the deubiquitinating (DUB) activity of the 19S RP DUBs. The compound can be used for treating cancer, in particular of cancer refractory to treatment by state-of-the-art chemotherapy. Also disclosed are corresponding methods of treatment and a pharmaceutical composition comprising the compound. |
| Applicant(s) |
LINDER, Stig et al |
| Representative Drug(s) |
D0A8EN |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2011094545 |
| Title |
Compositions and Methods for Enhancing Proteasome Activity. |
| Abstract |
Proteinopathies result from the proteasome not acting efficiently enough to eliminate harmful proteins and prevent the formation of the pathogenic aggregates. As described herein, inhibition of proteasome-associated deubiquitinase Usp 14 results in increased proteasome efficiency. The present invention therefore provides novel compositions and methods for inhibition of Uspl4, enhancement of proteasome activity and treatment of proteinopathies. |
| Applicant(s) |
President and Fellows of Harvard College |
| Representative Drug(s) |
D09CIC |
Drug Info
|
N.A. |
[1] |
